Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Lung Cancer (Amsterdam, Netherlands)|June 14, 2005
Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities--a multicenter phase II trialVera Hirsh, Jean Latreille, Harvey Kreisman, et al.
Cancer Chemotherapy and Pharmacology|December 2, 2010
A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patientsJonathan Hebb, Sarit Assouline, Caroline Rousseau, et al.
American Journal of Clinical Oncology|June 7, 2007
Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trialVera Hirsh, Pierre Desjardins, Burton M Needles, et al.
Current Oncology (Toronto, Ont.)|October 27, 2022
Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive ChemotherapyDavid Sanford, Pierre Desjardins, Brian Leber, et al.
Journal of the National Cancer Institute|May 28, 2010
Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trialCharles Lu, J Jack Lee, Ritsuko Komaki, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 7, 2011
Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II studyAaron D Schimmer, Wolfgang Herr, Mathias Hänel, et al.
Leukemia|December 18, 2018
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndromeJorge E Cortes, Florian H Heidel, Andrzej Hellmann, et al.
Journal of the National Cancer Institute|April 15, 2015
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12Matthew C Cheung, Annette E Hay, Michael Crump, et al.
Pageof 2